Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice
- Nat Metab. 2023 Dec;5(12):2075-2085. doi: 10.1038/s42255-023-00931-7.
- 1. Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Munich, Neuherberg, Germany.
- 2. German Center for Diabetes Research (DZD), Neuherberg, Germany.
- 3. Department of Physiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
- 4. Institute of Physiotherapy and Health Sciences, Academy of Physical Education, Katowice, Poland.
- 5. Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Zentrum München, Neuherberg, Germany.
- 6. TUM School of Medicine, Technical University of Munich, Munich, Germany.
- 7. Core Facility Pathology & Tissue Analytics, Helmholtz Munich, Neuherberg, Germany.
- 8. Novo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.
- 9. Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany.
- 10. Department of Chemistry, Indiana University, Bloomington, IN, USA.
- 11. Helmholtz Munich, Neuherberg, Germany.
- 12. Division of Metabolic Diseases, Department of Medicine, Technical University of Munich, Munich, Germany.
- 13. Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Munich, Neuherberg, Germany. [email protected].
- 14. German Center for Diabetes Research (DZD), Neuherberg, Germany. [email protected].
The development of single-molecule co-agonists for the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) is considered a breakthrough in the treatment of obesity and type 2 diabetes. But although GIPR-GLP-1R co-agonism decreases body weight with superior efficacy relative to GLP-1R agonism alone in preclinical1-3 and clinical studies4,5, the role of GIP in regulating energy metabolism remains enigmatic. Increasing evidence suggests that long-acting GIPR agonists act in the brain to decrease body weight through the inhibition of food intake3,6-8; however, the mechanisms and neuronal populations through which GIP affects metabolism remain to be identified. Here, we report that long-acting GIPR agonists and GIPR-GLP-1R co-agonists decrease body weight and food intake via inhibitory GABAergic neurons. We show that acyl-GIP decreases body weight and food intake in male diet-induced obese wild-type mice, but not in mice with deletion of Gipr in Vgat(also known as Slc32a1)-expressing GABAergic neurons (Vgat-Gipr knockout). Whereas the GIPR-GLP-1R co-agonist MAR709 leads, in male diet-induced obese wild-type mice, to greater weight loss and further inhibition of food intake relative to a pharmacokinetically matched acyl-GLP-1 control, this superiority over GLP-1 vanishes in Vgat-Gipr knockout mice. Our data demonstrate that long-acting GIPR agonists crucially depend on GIPR signaling in inhibitory GABAergic neurons to decrease body weight and food intake.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: GLP ReceptorResearch Areas: Metabolic Disease
-
target: GLP ReceptorResearch Areas: Metabolic Disease